Anti-NGAL (human)

Cat.No. ABS 062-14

Cat. No.
ABS 062-14
Product name
Anti-NGAL (human)
Description

Mouse monoclonal antibody

Specificity

ABS 062-14 is specific for human NGAL (neutrophil gelatinase-associated lipocalin)

Immunogen

Human recombinant NGAL coupled to carrier 

Application
Species reactivity (positive)
Human
Species reactivity (negative)
Not determined
Subclass

IgG2a/k

Gene ID
3934
Clone number
14
Epitope

Differs from those of HYB 211-01 and ABS 062-33.

Content

Available in 200 µL and 1 mL size.1 mg/mL +/- 15%. See Certificate of Analysis for details.

Purification
Protein-A purified
Form
Liquid
Solvent
0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage
4-8ºC without exposure to light. No precautions necessary during handling.
Target

Neutrophil gelatinase-associated lipocalin (NGAL; also called lipocalin 2, siderocalin and neutrophil lipocalin) is a member of the lipocalin family of proteins which bind and transport small lipophilic molecules. NGAL is released by activated neutrophils and occurs as 25-kDa glycosylated single protein chain monomers, which form dimers and small amounts of higher oligomers, as well as complexes with matrix metalloproteinase 9 (MMP-9; gelatinase B). Low level expression of NGAL in a variety of epithelia may be increased in inflammation or cancers. Expression of NGAL in the kidney is dramatically increased by acute kidney injury.

Application 1
ELISA
ABS 062-14 binds human NGAL coated onto a solid phase. 
ABS 062-14 forms a sandwich pair with HYB 211-01, ABS 038-04, -14, -15, -26 and ABS 062-33 for measuring human NGAL.
When ABS 062-14 is used as biotinylated detection antibody with ABS 062-33 as capture antibody, the assay is specific for NGAL monomer, cross-reacting <1% with NGAL homodimer.
 
The calibration curve of a sandwich assay for monomer human NGAL using ABS 062-33 as the capture antibody and ABS 062-14B as the biotinylated detection antibody (1).

1. Bangert et al (2013) The Monomer is the Major Form of NGAL in Urine and Plasma in Severe Sepsis J Am Soc Nephrol 24: 368A